Robert E Conway, a director of Nivalis Therapeutics, Inc., just received 7,650 options from the company. The strike price of the options received was $11.31, and these expire on January 01, 2028. Conway now owns at least 7,650 options on the company.

Some additional info was provided as follows:

The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. 100% of the shares subject to the option become vested and exercisable on January 2, 2019.

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To recei ve a free e-mail notification whenever Nivalis Therapeutics, Inc. makes a similar move, sign up!

Auto Refresh